Introduction {#Sec1}
============

Heart failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and clinical signs of congestion leading to frequent hospitalizations, poor quality of life, and shortened life expectancy \[[@CR1], [@CR2]\]. HF is a global pandemic that affects approximately 1--2% of the adult population in developed countries \[[@CR3]\], around 26 million people worldwide \[[@CR4]\], rising to ≥ 10% among people \> 70 years of age \[[@CR3]\], while the considerable HF health expenditures (\~ \$31 billion, in the USA in 2012) \[[@CR5]\] are expected to sharply increase with an aging population.

Despite advancements in medical, device-based, and surgical management of HF, outcomes remain non-satisfactory even in Western developed countries \[[@CR6]\]. Evidently, emphasis in investigating efficient research methodologies for HF management is one of the leading study directions that cannot be overlooked \[[@CR7]\].

Recently, machine learning (ML) algorithms have used computational methods to "learn" information directly from data, and their performance has been shown to improve proportionally with the number of high-quality samples \[[@CR8]\]. ML algorithms have been applied in different aspects of medicine \[[@CR9], [@CR10]\], including earlier disease detection \[[@CR11], [@CR12]\], improve diagnosis accuracy \[[@CR13]--[@CR16]\], identification of new physiological observations or patterns \[[@CR17]\], development of personalized diagnostics and/or therapeutic approaches \[[@CR18], [@CR19]\], research purposes \[[@CR20]\], etc.

The aim of this systematic review is to present the state of the art regarding the utility of ML techniques in comparison with conventional methods, in improving outcomes in HF patients.

Methods {#Sec2}
=======

This systematic review was guided by the PRISMA statement for systematic reviews and meta-analyses \[[@CR21]\].

Machine learning architectures {#Sec3}
------------------------------

Machine learning is an emerging technology paradigm that enables computers to learn patterns and insights from the data without being explicitly programmed. Details of ML algorithms adopted for managing HF patients are provided in the [Online Supplement](#MOESM1){ref-type="media"}.

Search strategy {#Sec4}
---------------

MEDLINE and Cochrane library databases were manually searched (G.B., G.T.) without year or language restriction or any other limits until May 29, 2019. The following algorithm was used: "((Machine learning OR deep learning OR bayes OR regression tree OR k means clustering OR vector machine OR artificial neural networks OR random forests OR decision trees OR nearest neighbours) AND heart failure)." Furthermore, the reference list of all the included studies as well as relevant review articles were also searched.

Study inclusion/exclusion criteria {#Sec5}
----------------------------------

All studies that included data about the implementation of ML techniques in HF (diagnosis, severity classification, prediction of adverse outcomes, identification of HF patients in electronic records, etc.) were considered as relevant and included in the systematic review. Review studies, studies that did not include data regarding HF patients and studies in experimental models, were excluded either at the title/abstract or at the full-text level.

Data extraction and statistical analysis {#Sec6}
----------------------------------------

The data extraction was performed by two independent investigators (G.B., J.Z.) and any disagreement was resolved by discussion.

We used a recently proposed score by Qiao \[[@CR22]\] for the quality assessment of ML studies (for details, please see the [Online Supplement](#MOESM1){ref-type="media"}).

Results {#Sec7}
=======

Search results {#Sec8}
--------------

As outlined in Supplementary Fig. [1](#MOESM1){ref-type="media"}, our search strategy revealed in total 122 relevant studies (one study provided data for two different outcomes \[OS21\]). Figure [1](#Fig1){ref-type="fig"} summarizes the different areas of ML implementation in HF patients.Fig. 1Areas of application of machine learning in the management of heart failure patients

Classification of HF patients {#Sec9}
-----------------------------

Our search retrieved four streams of studies regarding the implementation of ML techniques in patient classification, pertaining to HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and in different HFpEF subtypes. The variables for HF characteristics included demographics, clinical examination, laboratory exams, medical history, electrocardiographic data, echocardiographic data, and heart rate variability (HRV) (Supplementary Table [1](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high quality (intermediate: 2 studies, high: 2 studies) in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}). This suggests that the provided outcomes are less prone to different kinds of bias.

Modern classification methods have shown a better performance over conventional classification methods that could lead to better management in clinical practice (Table [1](#Tab1){ref-type="table"}).Table 1Comparison of machine learning algorithms with traditional methods in the management of heart failureAuthorJournalYearOutcomeComparison between machine learning and conventional methodsConclusionMachine learning modelsConventional methodsClassification of HF patients  Austin PC*Journal of Clinical Epidemiology*2013DiscriminationHFpEF vs HFrEFModelAUCModelAUCConventional LR performed at least as well as modern methodsRegression tree0.683LR0.780Bagged regression tree0.733Random forest0.751Boosted regression tree (depth 1)0.752Boosted regression tree (depth 2)0.768Boosted regression tree (depth 3)0.772Boosted regression tree (depth 4)0.774CRT response  Kalscheur MM*Circ Arrhythm Electropysiol*2018All-cause mortality or HF hospitalization in CRT recipientsAUC valuesRF model (0.74, 95% CI 0.72--0.76)Sequential minimal optimization to train a SVM (0.67, 95% CI 0.65--0.68)AUC valuesMultivariate LR (0.67, 95% CI 0.65--0.69)The improvement in AUC for the RF model was statistically significant compared to the other models, *p* \< 0.001Data extraction  Zhang R*BMC Med Inform Decis Mak*2018HF information (NYHA) extraction from clinical notesRF, *n*-gram features → *F*-measure 93.78%, recall 92.23%, precision 95.40%, SVM → *F*-measure 93.52%, recall 93.21%, precision 93.84%LR → *F*-measure 90.42%, recall 90.82%, precision 90.03%ML-based methods outperformed a rule-based method. The best machine learning method was an RFHF diagnosis  Nirschi JJ*PlosOne*2018HF diagnosis using biopsy imagesAUC valueRF 0.952Deep learning 0.974AUC valuePathologists 0.75ML models outperformed conventional methods  Rasmy L*J Biomed Inform*2018HF diagnosisAUC valueRecurrent NN 0.822AUC valueLR 0.766ML outperformed conventional methods  Son CS*J Biomed Inform*2012HF diagnosisRough sets based decision-making model → accuracy 97.5%, SENS 97.2%, SPE 97.7%, PPV 97.2%, NPV 97.7%, AUC 97.5%LR-based decision-making model → accuracy 88.7%, SENS 90.1%, SPE 87.5%, PPV 85.3%, NPV 91.7%, AUC 88.8%ML models outperformed conventional methods  Wu J*Med Care*2010HF diagnosisBoosting using a less strict cut-off had better performance compared to SVMThe highest median AUC (0.77) was observed for LR with Bayesian information criterionLR and boosting were, both, superior to SVMIdentification of HF patients  Blecker S*JAMA Cardiology*2016Identification of HF patientsML using notes and imaging reports → (developmental set) AUC 99%, SENS 92%, PPV 80%. (Validation SET) AUC 97%, SENS 84%, PPV 80%LR using structured data → (developmental set) AUC 96%, SENS 78%, PPV 80%. (Validation SET) AUC 95%, SENS 76%, PPV 80%ML models improved identification of HF patients  Blecker S*J Card Fail*2018Identification of HF hospitalizationML with use of both data → (developmental set) AUC 99%, SENS 98%, PPV 43%. (Validation SET) AUC 99%, SENS 98%, PPV 34%LR using structured data, notes, and imaging reports → (developmental set) AUC 96%, SENS 98%, PPV 14%. (Validation SET) AUC 96%, SENS 98%, PPV 15%ML models performed better in identifying decompensated HF  Choi E*Journal of AMIA*2017Predicting HF diagnosis from EHRAUC values12-month observation →NN model 0.777MLP with 1 hidden layer 0.765SVM 0.743K-NN 0.730AUC values12-month observation →LR 0.747ML models performed better in detecting incident HF with a short observation window of 12--18 monthsPrediction of outcomes  Austin PC*Biom J*201230-day mortalityAUC valuesRegression tree 0.674Bagged trees 0.713Random forests 0.752Boosted trees---depth one 0.769Boosted trees---depth two 0.788Boosted trees---depth three 0.801Boosted trees---depth four 0.811AUC valuesLR 0.773Ensemble methods from the data mining and ML literature increase the predictive performance of regression trees, but may not lead to clear advantages over conventional LR models  Austin PC*J Clin Epidemiol*2010In-hospital mortalityAUC valuesLR modelsRegression trees 0.620--0.651AUC valuesLR 0.747--0.775LR predicted in-hospital mortality in patients hospitalized with HF more accurately than did the regression trees  Awan SE*ESC Heart Failure*201930-day readmissionsAUC valuesMLP 0.62Weighted random forest 0.55Weighted decision trees 0.53Weighted SVM models 0.54AUC valuesLR 0.58The proposed MLP-based approach is superior to other ML and regression techniques  Fonarow GC*JAMA*2005In-hospital mortalityAUC valuesCART model (derivation cohort 68.7%; validation cohort 66.8%)AUC valuesLR model (derivation cohort 75.9%; validation cohort 75.7%)Based on AUC, the accuracy of the CART model (derivation cohort 68.7%; validation cohort 66.8%) was modestly less than that of the more complicated LR model (derivation cohort75.9%; validation cohort 75.7%)  Frizzell JD*JAMA Cardiol*201630-day readmissions*C*-statisticsTree-augmented naive Bayesian network 0.618RF 0.607Gradient-boosted 0.614Least absolute shrinkage and selection operator models 0.618C-statisticsLR 0.624ML methods showed limited predictive ability  Golas SB*BMC Med Inform Decis Mak*201830-day readmissionsAUC valuesGradient boosting 0.650 ± 0.011Maxout networks 0.695 ± 0.016Deep unified networks 0.705 ± 0.015AUC valuesLR 0.664 ± 0.015Deep learning techniques performed better than other traditional techniques  Hearn J*Circ Heart Fail*2018Clinical deterioration (i.e., the need for mechanical circulatory support, listing for heart transplantation, or mortality from any cause)AUC valuesppVo2 0.800 (0.753--0.838)Staged LASSO 0.827 (0.785--0.867)Staged NN 0.835 (0.795--0.880)BxB LASSO 0.816 (0.767--0.866)BxB NN 0.842 (0.794--0.882)AUC valuesCPET risk score 0.759 (0.709--0.799)NN incorporating breath-by-breath data achieved the best performance  Kwon JM*Echocardiography*2019Hospital mortalityAUC valuesDeep learning 0.913RF 0.835AUC valuesLR 0.835MAGGIC score 0.806GWTG score 0.783The echocardiography-based deep learning model predicted in-hospital mortality among HD patients more accurately than existing prediction models  Phillips KT*AMIA Annu Symp Proc*2005MortalityAUC levelsNearest neighbor 0.823NN 0.802Decision tree 0.4975AUC valuesStepwise LR 0.734Data mining methods outperform multiple logistic regression and traditional epidemiological methods  Mortazavi BJ*Circ Cardiovasc Qual Outcomes*2016HF readmissions*C*-statisticsBoosting 0.678*C*-statisticsLR 0.543Boosting improved the c-statistic by 24.9% over LR  Myers J*Int J Cardiol*2014Cardiovascular deathAUC valuesArtificial NN 0.72Cox PH models 0.69AUC valuesLR 0.70An artificial NN model slightly improves upon conventional methods  Panahiazar M*Stud Health Technol Inform*20155-year mortalityAUC valuesRF 62% (baseline set), 72% (extended set)Decision tree 50% (baseline set), 50% (extended set)SVM 55% (baseline set), 38% (extended set)AdaBoost 61% (baseline set), 68% (extended set)AUC valuesLR 61% (baseline set), 73% (extended set)LR and RF return more accurate models  Subramanian D*Circ Heart Fail*20111-year mortality*C*-statisticsEnsemble model using gentle boosting with 10-fold cross-validation 84%*C*-statisticsΜultivariate LR model using time-series cytokineMeasurements 81%The ensemble model showed significantly better performance  Taslimitehrani V*J Biomed Inform*20165-year survivalPrecisionSVM 0.2,CPXR (log) 0.721RecallSVM 0.5CPXR (log) 0.615AccuracySVM 0.66CPXR 0.809PrecisionLR 0.513RecallLR 0.506AccuracyLR 0.717CPXR is better than logistic regression, SVM, random forest and AdaBoost  Turgeman L*Artif Intell Med*2016Hospital readmissionsAUC valuesNN 0.589 (train), 0.639 (test)Naïve Bayes 0.699 (train), 0.676 (test)SVM 0.768 (train), 0.643 (test)CART decision tree 0.529 (train), 0.556 (test)Ensemble models C5 0.714 (train), 0.693 (test)CHAID decision tree 0.671 (train), 0.691 (test)AUC valuesLR 0.642 (train), 0.699 (test)A dynamic mixed-ensemble model combines a boosted C5.0 model as the base ensemble classifier and SVM model as a secondary classifier to control classification error for the minority class  Wong W*Scientific World Journal*2003Mortality (365 days models)AUC valuesMLP 69%Radial basis function 67%AUC valuesLR 60%NNs are able to outperform the LR in terms of sample prediction  Yu S*Artif Intell Med*201530-day HF readmissionsAUC valuesLinear SVM 0.65Poly SVM 0.61Cox PH 0.63AUC valuesIndustry standard method (LACE) 0.56The ML models performed better compared to standard method  Zhang J*Int J Cardiol*2013Death or hospitalizationAUC valuesDecision trees 79.7%AUC valuesLR 73.8%Decision trees tended to perform better than LR models  Zhu K*Methods Inf Med*201530-day readmissionsAUC valuesRF 0.577SVM 0.560Conditional LR 1 = 0.576Conditional LR 2 = 0.608Conditional LR 3 = 0.615AUC valuesStandard LR 0.547Stepwise LR 0.539LR after combining ML outperforms standard classification models  Zolfaghar KIn *2013 IEEE International Conference on Big Data*2013HF readmissionsAUC valuesMulticare health systems modelRF 62.25%AUC valuesMulticare health systems modelLR 63.78%Yale modelLR 59.72%ML random forest model does not outperform traditional LR model*AUC* area under the receiver operating curve, *CPET* cardiopulmonary exercise test, *HF* heart failure, *LR* logistic regression, *ML* machine learning, *MLP* multilayer perceptron, *NN* neural networks, *NPV* negative prognostic value, *PH* proportional hazard, *PPV* positive prognostic value, *ppVo2* predicted peak oxygen uptake, *RF* random forest, *SENS* sensitivity, *SPE* specificity, *SVM* support vector machine

Discrimination of HF patients from subjects with no HF {#Sec10}
------------------------------------------------------

Our search retrieved 30 studies regarding the discrimination of HF patients, from subjects with no HF (Supplementary Table [2](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high quality (intermediate: 14 studies, high: 16 studies) in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}), suggesting that the provided outcomes are less prone to different kinds of bias (Table [1](#Tab1){ref-type="table"}).

The general process of ML techniques for HF discrimination in a non-acute setting is to estimate the probability of HF based on prior clinical history of the patient, the presenting symptoms, physical examination, and resting electrocardiogram. Application of ML techniques for HF discrimination on the available data is less time consuming and more accurate than traditionally used statistics or expert methods. Accurate HF discrimination via ML techniques allows for treatments and interventions to be delivered in a more efficient and targeted way, permits assessment of the HF patient's progress, prevents condition worsening, affects positively the patient's health, and contributes to decrease of medical costs. The main difference between the ML methods for HF discrimination lies in the different heart rate variability features employed to detect HF.

Sanchez-Martinez et al. (2017) used multiple kernel learning method to differentiate cardiac and non-cardiac cause of breathlessness and revealed processes leading to HFpEF with a specificity as high as 90.9% \[OS42\]. It should be noted that many ML studies found that feature selection determines the performance of the model, and thus automatic feature selection scheme is needed. Such automatic feature selection is also an advantage of the latest ML methods.

Prediction of outcomes {#Sec11}
----------------------

Our search retrieved 58 studies regarding the implementation of ML techniques in the prediction of major outcomes in HF patients. Specifically, the measured outcomes that were studied include mortality, hospitalizations, decompensations, implantable cardioverter defibrillator (ICD) implantations for secondary prevention, need for mechanical circulatory support, heart transplantation, pump failure, myocardial infarction, strokes, and ventricular assist device implantation (Supplementary Table [3](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high quality (intermediate: 39 studies, high: 21 studies) in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}). This suggests that the provided outcomes are less prone to different kinds of bias (Table [1](#Tab1){ref-type="table"}).

Existing studies utilize demographic, clinical, laboratory, and electrocardiographic data (short-term or long-term HRV measures) as the main predictors and incorporate multiple classifiers such as support vector machine (SVM), classification and regression trees (CART), *k*-nearest neighbor algorithm (k-NN). These methods can work well separately, or collectively through certain ensemble learning techniques \[[@CR23]\].

Identification of HF patients with similar characteristics from electronic medical records {#Sec12}
------------------------------------------------------------------------------------------

Our search retrieved 6 studies regarding the role of ML techniques in the identification of HF patients from a pool of hospitalized patients or identification of patients with similar characteristics (Supplementary Table [4](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high quality (intermediate: 2 studies, high: 4 studies) in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}), suggesting that the provided outcomes are less prone to different kinds of bias.

Specifically, Cikes et al. (2019) used unsupervised machine learning-based phenogrouping in HF to provide a clinically meaningful classification of a phenotypically heterogeneous HF cohort by integrating clinical parameters and full heart cycle imaging data \[OS127\]. Pakhomov et al. (2007) used predictive ML techniques and language processing contained in the electronic medical records, to identify patients with HF with 96% specificity \[OS114\]. Panahiazar et al. (2015) developed a multidimensional patient similarity assessment technique to leverage multiple types of information from the electronic health records and predicted a medication plan for each new patient on a cohort of HF patients with area under the curve (AUC) of 0.74 \[OS116\]. Blecker et al. (2016) employed ML techniques and improved real-time identification of hospitalized patients with HF using both structured and unstructured electronic health records data, demonstrating high efficiency of ML analytics \[OS112\]. Although the accuracy varies, existing studies demonstrated that it is feasible to use ML to facilitate individualized interventions for hospitalized patients with HF.

Real-time identification of HF syndrome among hospitalized individuals is of great importance, as it likely to result in improvement of patient care and outcomes. Use of ML techniques for the identification of HF patients from electronic medical records and identification of HF patients with similar characteristics may lead to delivery of more tailored clinical care.

Decision support from clinical notes {#Sec13}
------------------------------------

Another meaningful consideration for the implementation of ML techniques is the extraction of important clinical data from diverse sources of narrative text. Our search found 3 studies regarding this aim (Supplementary Table [5](#MOESM1){ref-type="media"}). All studies were classified as high quality in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}).

Kim et al. (2013) improved HF information extraction through developing a natural language processing-based application to extract congestive HF treatment performance measures from echocardiographic reports (i.e., the source domain) with high recall and precision (92.4% and 95.3%, respectively) \[OS117\]. Meystre et al. (2017) demonstrated that the rich and detailed clinical information extracted from narrative notes may help improve management and outpatient treatment of HF patients \[OS118\]. Zhang et al. (2018) used random forest-based model to identify New York Heart Association (NYHA) class from clinical notes, with *F*-measure 93.78% \[OS119\].

The extracted clinical and medical information is critical to the understanding of a patient's clinical and medication status for better healthcare safety and quality. Furthermore, these algorithms can identify patients who do not receive appropriate HF medications and thus may help reduce the number of undertreated patients (Table [1](#Tab1){ref-type="table"}).

Prediction of outcomes in left ventricular assist device (LVAD) patients {#Sec14}
------------------------------------------------------------------------

Our search retrieved 7 studies that focused on the prediction of outcomes in LVAD patients (Supplementary Table [6](#MOESM1){ref-type="media"}). All studies were classified as high quality in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}).

Loghmanpour et al. (2015) developed a Bayesian network-based risk stratification model to predict the short-term and long-term LVAD mortality with approximately 95% accuracy in predicting mortality at 30 days post-implant \[OS120\]. Mason et al. (2010) employed neural networks and waveform analysis methods for the non-invasive prediction of the pulsatile LVAD (HeartMate XVE (Thoratec Corporation, Pleasanton, CA)) pump failure within 30 days post-implantation \[OS123\]. Wang et al. (2012) found that the decision tree method can quantitatively provide improved prognosis of RV support through encoding the non-linear, synergic interactions among pre-operative variables, with an AUC of 0.87 \[OS125\]. The method can be used as an effective prognostic tool for triage of LVAD therapy. Lüneburg et al. (2019) used a U-net convolutional neural network for driveline tube segmentation and showed that the deep learning techniques can efficiently recognize LVAD on driveline exit site images \[OS126\]. Michaels and Cowger provide a review of the HF risk assessment as a referral guide for advanced HF therapies \[[@CR24]\].

LVAD therapy is a life-saving treatment option as a destination therapy for end-stage HF patients who are ineligible for heart transplantation. However, the identification of high-risk patients who are prone to LVAD complications or adverse outcomes is crucial for patient selection who will benefit from this therapy (Table [1](#Tab1){ref-type="table"}).

Prediction of cardiac resynchronization therapy response {#Sec15}
--------------------------------------------------------

Our search retrieved 5 studies regarding the role of ML techniques in CRT response prediction to overcome the challenge of significant nonresponse rates of current guidelines (Supplementary Table [7](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high (intermediate: 1 study, high: 4 studies) quality in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}).

Kalscheur et al. (2018) employed random forest method to predict cardiac resynchronization therapy outcomes and showed that the ML method can utilize the information of bundle branch block morphology and QRS duration to derive the risk of the composite end point of all-cause mortality or HF hospitalization \[OS128\]. Feeny et al. (2019) analyzed CRT patients using ML techniques and showed that the performance can be improved incrementally by adding up to nine variables demonstrating that ML models have the potential to improve the shared decision-making in CRT \[OS131\].

Due to the high percentage of non-responders to CRT therapy \[[@CR25]\], the reported performance of ML algorithms in the prediction of patients who will benefit from this treatment option is of great clinical importance. The implementation of ML algorithms in clinical practice is expected reduce the number of CRT patients who will not benefit by this high cost treatment option who is related with higher rates of peri- and post-procedural complications.

Prediction of other HF-related outcomes {#Sec16}
---------------------------------------

Our search also retrieved 8 studies regarding the role of ML techniques in alternative outcomes (i.e., prediction of treatment adherence \[OS137, OS138\], prediction of adherence use of remote HF monitoring systems \[OS133\], association of HF symptoms with depression \[OS134\], prediction of LV filling pressures \[OS132\], chronic HF management \[OS135\], prediction of missing data in wireless health projects \[OS136\], pathways delineation of death in patients with LVAD \[OS139\] (Supplementary Table [8](#MOESM1){ref-type="media"}). All studies were classified as intermediate-high quality (intermediate: 2 studies, high: 6 studies) in the quality assessment (Supplementary Table [9](#MOESM1){ref-type="media"}).

Specifically, Son et al. (2010) observed superior performance of support vector machine to predict medication adherence of patients with HF \[OS138\]. Karanasiou et al. (2016) found that ML methods can predict the medication/nutrition/physical activity adherence of patients with HF with an accuracy ranging from 0.82 to 0.91 \[OS137\]. Evangelista et al. (2017) predicted HF patient's adherence use of remote health monitoring systems with ML with an accuracy that ranged from 87.5 to 94.5% \[OS133\]. Graven et al. (2018) revealed the relationship between HF and depression with random forest algorithms \[OS134\]. Dini et al. (2010) developed an echo-Doppler decision model to predict left ventricular filling pressure in patients with HF \[[@CR26]\]. Specifically, patients were correctly allocated according to pulmonary capillary wedge pressure with a sensitivity of 87% and specificity of 90% \[OS132\]. Seese et al. (2019) used a hierarchical clustering ML approach to create a descriptive model for delineating the pathways to death in patients with a LVAD, suggesting that there are two predominant types of adverse events which lead to mortality associated with multiorgan dysfunction (group 1: bleeding and infection and group 2: renal and respiratory complications) \[OS139\]. Another application of ML techniques has aimed to improve follow-up monitoring and management of chronic HF patients, following hospitalization \[OS135\].

Finally, a significant problem in the implementation of wireless health projects is the presence of missing data due to system misuse, non-use, and failure. Suh et al. (2011) adopted ML techniques to predict both non-binomial and binomial data missing data in wireless health projects with accuracies ranged between 85.7 and 98.5% \[OS136\].

Discussion {#Sec17}
==========

The main finding of our systematic review is that ML techniques may play a unique role in the contemporary management of HF patients. This includes classification of HF patients into categories who will benefit from specific treatment strategies, discrimination of HF patients from no HF subjects or differential diagnosis of HF from other conditions with similar clinical presentation and prediction of outcomes in different patient populations, such as those with LVAD and CRT.

An important advantage of ML techniques compared to conventional prognostic algorithms is that ML techniques do not assume linear relationships between variables and outcomes, thus resulting in better performance in identifying individualized outcome predictions \[[@CR27]\]. Recent data show that ML algorithms outperform logistic regression models in the prediction of HF outcomes \[[@CR28]--[@CR30]\]. Specifically, the better accuracy of ML algorithms compared to conventional tools has been demonstrated for the prediction of mortality in the setting of acute HF \[[@CR30]\], mortality and hospitalization for HFpEF \[[@CR29]\], and hospital readmissions \[[@CR31]\]. Nonetheless, there is still room for improvement of ML techniques in predicting outcomes in these patients. For example, in a recent study, ML algorithms showed limited improvement in the prediction of all-cause mortality and HF hospitalization compared to traditional logistic regression analysis when using binary variables, while after including continuous variables, ML approaches generally performed better than logistic regression modeling \[[@CR28]\].

Early diagnosis of the HF syndrome is the cornerstone for the early initiation of appropriate treatment and improving patients' prognosis. Therefore, existence of an objective, non-invasive, and low-cost tool for the diagnosis of HF is of great importance. Our search showed that ML techniques have a good discrimination performance in identifying HF patients by using different easily obtainable variables including demographics, clinical examination findings, echocardiographic parameters, electrocardiographic indices, etc. \[OS24, OS26\]. ML techniques can provide real-time identification of in-hospital patients with HF and extraction of important clinical as well as medication related information from unstructured data (i.e., clinical notes) that result in the improvement of HF management and treatment \[OS113, OS114, OS117--119\]. This is extremely important because hospitalized patients with HF often receive insufficient education and suboptimal transition of care planning, early post-discharge follow-up, or secondary prevention management, leading to high readmission rates, which in turn are associated with an unacceptably high rates of morbidity and mortality \[OS153\].

Classification of HF patients into subtypes with different prognosis and treatment needs is clinically important. Recent guidelines classify HF patients into HFpEF, HF with mid-range ejection fraction (HFmrEF) and HFrEF mainly using EF values \[[@CR3]\]. However, this classification has some disadvantages especially due to the definition of HFpEF and HFmrEF patients. ML-based models can sufficiently classify HF patients (including the gray zone) using different clinical variables \[OS18--21\] The clinical implications for patient-specific classification of HF patients cannot be overemphasized. For example, in light of the favorable results of sacubitril-valsartan in women, but not men with HFpEF \[OS154\], it has been argued that a different cut-off value for EF should be used in women vs. men. In the future, ML techniques may be able to apply sex-specific classification criteria for HF patients, which will facilitate clinical decisions regarding implementation of appropriate therapy. Another example refers to phenomapping of patients with HFpEF to different phenotypic groups, with different prognosis and response to pharmacologic interventions, such as spironolactone \[OS155\]. Given that no pharmacologic therapy has been shown to improve clinical outcomes in HFpEF \[OS156\], identification of a subset of patients with HFpEF who might benefit from certain medications becomes of utmost importance.

Our search showed that ML techniques have been applied successfully in the identification of high-risk patients and in the early initiation of appropriate treatment with the aim of reducing HF related mortality and hospitalizations. Different risk scores have been proposed for the identification of high-risk patients \[OS140--142\]. Specifically, Ahmad et al. \[[@CR19]\] implement ML techniques to classify HF patients into four groups using the eight strongest derived predictors (age, creatinine, hemoglobin, weight, heart rate, systolic blood pressure, mean arterial pressure, and income) of mortality. This type of classification proved to be superior to current classification methods of HF patients, in terms of prognostication and response to medications, and may replace patient classification in different clinical settings.

Prediction of patients who may respond to CRT therapy is of great importance \[OS143, OS144\]; however, approximately 30% of CRT recipients do not respond to this treatment \[OS145\]. ML techniques have been successfully implemented in creating score models with improved measure estimates regarding the prediction of CRT responders, compared to conventional techniques \[OS146--148\]. As a result, risk scores produced by employing ML techniques can become the cornerstone for appropriate CRT candidate selection. In addition, ML techniques have been implemented with success in predicting outcomes of LVAD patients, implying that ML techniques may play an even important role in the decision-making regarding LVAD candidates in the future.

Furthermore, our review also found that ML techniques have been applied in other aspects of the management of HF patients, e.g., ML techniques can be applied in the identification of patients who may adhere to the prescribed medications or may need additional measured for treatment adherence \[OS137, OS138\]. Another significant role of ML techniques in the management of HF patients is the identification of HF patients who are at high risk for other comorbidities (i.e., depression) \[OS134\], or in remote HF monitoring systems resulting in improvement of HF clinical outcomes \[OS133, OS149--151\]. Effective ML techniques have been implemented to protect implantable devices from cybersecurity attacks \[OS152\]. Since ML algorithms have been implemented in identifying risk factors for predicting treatment-related discontinuations in various clinical settings \[[@CR32], [@CR33]\], identification of HF patients who are at increased risk of treatment discontinuation because of drug related adverse effects may be another important area for ML algorithm implementation.

Finally, while a series of critical issues (i.e., the role of physicians and patients in the decision-making process, reliability, transparency, accountability, liability, handling of personal data, different kinds of bias, continuous monitoring of AI adverse events/system failure, cybersecurity, and system upgrading) have led to skepticism with respect to the implementation and adoption of AI algorithms in clinical practice, the ML impact on health economics, is expected to be beneficial to both patients and health insurance providers, justified by an earlier and more accurate diagnosis, reduction of unnecessary expensive diagnostic exams, and selection of optimal candidates for expensive treatment options. Consequently, the implementation of ML algorithms in clinical practice is a complex process and an integrated regulatory framework for the research, development and adoption of ML in medicine, is needed.

Study limitations {#Sec18}
-----------------

The following limitations should be considered: a quantitative synthesis was inappropriate because of the heterogeneity between the included studies regarding the reported outcomes and measured estimates. Therefore, the reported outcomes in each included study are prone to different kinds of biases mainly depended on the ML method that was used. Moreover, the outcomes of a number of studies should be interpreted with caution because of the small number of patients. Finally, our results should be interpreted in light of the fact the tool for quality assessment of the included studies is relatively new and has not been validated in multiple studies.

Conclusions {#Sec19}
===========

ML techniques play an important role in different aspects of the management of HF patients and show inspiring promise in the efficient construction of methodologies aiming to improve HF diagnosis, management, and prediction of outcomes in different clinical settings, with generally an improved performance compared to conventional techniques.

While a regulatory framework for the implementation of ML in clinical practice is needed, intelligent analysis of health data with ML techniques still acts as auxiliary decisional role and at the moment cannot replace clinical cardiologists.
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